	US 12,281,339 B2
	Combination cancer immunotherapies with arginine depletion agents
Elena Brin, San Diego, CA (US); and Wei He, San Diego, CA (US)
Assigned to POLARIS GROUP, Grand Cayman (KY)
Filed by Polaris Group, Grand Cayman (KY)
Filed on Jul. 5, 2017, as Appl. No. 15/641,819.
Claims priority of provisional application 62/515,807, filed on Jun. 6, 2017.
Claims priority of provisional application 62/358,479, filed on Jul. 5, 2016.
Prior Publication US 2018/0010114 A1, Jan. 11, 2018
Int. Cl. C12N 9/96 (2006.01); A61K 47/10 (2017.01)

CPC C12N 9/96 (2013.01) [A61K 47/10 (2013.01); C12Y 305/03006 (2013.01)]

32 Claims

1. A method of treating a cancer in a subject in need thereof, comprising administering to the subject

(a) an ADI polypeptide; and

(b) an immune checkpoint modulatory agent wherein said agent is a PD-1 antagonist or a PD-L1 antagonist; and

wherein (i) the cancer in the subject is one targeted for immunotherapy treatment and (ii) the ADI-polypeptide is administered to enhance the immune activity of the immune checkpoint modulatory agent.